Xenetic Biosciences (XBIO) Registration Filing summary

Company overview and business model

• Focuses on developing immune-oncology technologies for hard-to-treat cancers, with a proprietary DNase platform targeting NETs to improve cancer treatment outcomes.

• DNase program is advancing into clinical trials as adjunctive therapy for pancreatic carcinoma and solid tumors.

• PolyXen platform, licensed to industry partners, enables extended half-life and stability for protein and peptide drugs, generating ongoing royalty revenue.

• Drug candidates are in development stage; none have received regulatory approval.

• Holds a broad patent portfolio, with recent internal focus on licensing and advancing the DNase platform.

Financial performance and metrics

• As of September 30, 2024, public float was approximately $5.6 million, based on 1,303,696 shares at $4.32 per share.

• Aggregate market value of outstanding common equity held by non-affiliates is less than $75 million.

Use of proceeds and capital allocation

• Net proceeds will be used for general corporate purposes, including acquisitions, funding development programs and clinical trials, repayment of indebtedness, and working capital.

• Specific allocation of proceeds will be detailed in the relevant prospectus supplement at the time of each offering.